You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Group of experts slams critics of India's Covid vaccine approval process

A group of doctors and scientists on Thursday hit out at the critics of the government's approval to two Covid-19 vaccines, especially the one produced indigenously by Bharat Biotech

Topics
Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Press Trust of India  |  New Delhi 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Representational image of Covaxin

A group of doctors and scientists on Thursday hit out at the critics of the government's approval to two COVID-19 vaccines, especially the one produced indigenously by Bharat Biotech, alleging that their "reprehensible" utterances are causing huge credibility crisis for the Indian scientific community.

In a statement signed by 45 medical professionals and scientists, the group expressed shock at the "irresponsible statements of vested interests" and accused these critics of casting aspersions on Indian experts' integrity by making politicised statements to doubt the recent research in the field of COVID-19 vaccines.

The statement, whose signatories include former AIIMS directors T D Dogra and M C Mishra, former CSIR-IICT, Hyderabad, chief scientist A Gangagni Rao and Manipal Education and Medical Group's Chairman of Board Ranjan Pai, said these vaccines are our gift to the humanity.

India had recently approved two vaccines, Oxford-Astra Zeneca's Covishield being manufactured by Serum Institute of India and Bharat Biotech's Covaxin, for emergency-use authorisation.

Some experts and a few opposition leaders had questioned the decision, noting that the phase three trial of Covaxin was not yet complete and its efficacy data was not available.

The government has insisted that it has followed all procedure.

"We urge upon our fellow countrymen to reject the manipulations of vested interests aimed at politicisation and defamation of our nation's scientists, doctors and scientific community for their narrow vested interests. They need to realise that by doing so, these vested interests are wrecking the highly valued and credible scientific edifice created by us, which has made India a global leader in the export of vaccines all over the world," the statement said.

"Such reprehensible utterances are causing huge credibility crisis for the Indian scientific community who have devoted their lifetimes to make India a name to reckon with in export of vaccines all over the world," it added.

The statement's signatories noted that India has emerged as a global leader in supply of vaccines to the world due to the efforts of its doctors and scientists.

Vaccines are exported from India to over 188 countries, and the Indian vaccine market reached a value of Rs 94 billion in 2019 and has still got unused potential for the future, they said.

Defending the vaccines, they said Covaxin has been developed on 'Vero cell platform', which has a well established track record of safety and efficacy globally.

Phase I and Phase II clinical trials of Covaxin were conducted in approximately 800 subjects and the results have demonstrated that the vaccine is safe and provides a robust immune response, they noted and said more than 22,000 volunteers have been enrolled to determine its efficacy for phase three studies.

Though efficacy data is not available for Covaxin but safety parameters are very good, and there is a robust immune response seen with this vaccine, they said.

"Further this vaccine is a whole virus inactivated vaccine which may have better protection even against mutant strains of the virus as the immune response will be against multiple antigens and not only against spike protein," the experts said.

They noted that Covishield still needs data from India on immunogenicity and efficacy but has been given emergency use authorisation keeping in mind the difficult times due to COVID pandemic.

This vaccine has undergone phase I, II and III clinical trials of safety, immunogenicity and efficacy abroad, and its overall efficacy was found to be 70.42 per cent, they added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, January 14 2021. 18:23 IST
RECOMMENDED FOR YOU